{"filings":[{"id":2550077,"accession_number":"0001087294-26-000064","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2026-08-28T21:08:50+00:00","items":["7.01"],"status":"ready","headline":"Cumberland delays release of FIGHT DMD ifetroban long-term data; no new timeline","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 FIGHT DMD open-label extension long-term safety/efficacy data for ifetroban not yet available.","Company no longer expects to present data in August 2026 as stated at PPMD conference on June 26, 2026.","Data was originally expected at Parent Project Muscular Dystrophy annual conference in Orlando.","Cumberland will present at a future date when data becomes available; no revised timeline given.","Ifetroban is an oral candidate for Duchenne muscular dystrophy heart disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2054037,"accession_number":"0001087294-26-000058","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2026-08-04T21:20:45+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cumberland closes $100M Apotex deal, pays $1.50 special dividend, reports Q2 loss","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed $100M strategic transaction with Apotex Health; received $111M total including inventory and transition services.","Paid special cash dividend of $1.50 per share on July 31, 2026 to shareholders of record July 23.","Q2 2026 loss from continuing operations $3.1M; net loss $4.1M; cash $4M; retired $5.2M credit line.","Phase 2 ifetroban in DMD showed biomarker evidence of cardiac protection; cancer metastasis study met safety endpoint.","Metastatic recurrence 17% ifetroban vs 50% placebo (p=0.09); deaths from metastasis 0% vs 30% (p=0.037)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1612519,"accession_number":"0001087294-26-000055","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2026-07-13T21:28:01+00:00","items":["8.01"],"status":"ready","headline":"Cumberland Pharmaceuticals declares special dividend of $1.50/share, authorizes $5M buyback","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Special cash dividend of $1.50 per share, payable July 31, 2026 to holders of record July 23, 2026.","Board authorized open-market share repurchase program of up to $5 million, replacing prior $10M program.","Dividend follows $100M cash received from Apotex strategic transaction; up to $11M additional payments expected.","Several board members plan to establish new share purchase plans to increase holdings.","Company retains pipeline of ifetroban for Duchenne, systemic sclerosis, IPF, and cancer metastasis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1388127,"accession_number":"0001104659-26-079871","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2026-07-01T20:15:26+00:00","items":["1.01","1.02","2.01","5.02","8.01","9.01"],"status":"ready","headline":"Cumberland closes $100M sale of branded products to Apotex; retains ifetroban pipeline","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sold Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ for $100M cash.","Over 99% of shareholder votes supported the transaction.","Company retains ifetroban candidates for Duchenne, systemic sclerosis, IPF, cancer metastasis.","Terminated $5.3M Pinnacle Bank credit facility; repaid in full.","Pro forma shows ~$110M cash, no product revenue, net loss from continuing ops."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1278802,"accession_number":"0001087294-26-000053","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2026-06-25T21:00:32+00:00","items":["5.07"],"status":"ready","headline":"Shareholders approve sale of Cumberland's FDA-approved products to Apotex","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Shareholders voted 10,492,455 For (99.84% of votes cast), 15,904 Against, 1,267 Abstain.","Transaction involves sale of FDA-approved commercial products and related assets to Apotex Inc.","Approval allows Cumberland to integrate products with Apotex's U.S. branded business per April 22, 2026 APA.","Special meeting held June 24, 2026; quorum of 70.14% of outstanding shares (10,509,626 shares represented)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91199,"accession_number":"0001087294-26-000046","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cumberland Pharma enters $100M strategic transaction with Apotex, reports Q1 revenue $9.1M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Entered $100M cash deal to sell FDA-approved brand portfolio to Apotex Inc.; subject to shareholder approval and closing conditions.","Q1 net revenue $9.1M (+5% ex-$3M prior-year milestone); net loss $3.3M; adjusted loss $0.13/share.","FDA granted Fast Track Designation for ifetroban in Duchenne Muscular Dystrophy; Phase II study showed breakthrough results.","Ended quarter with $11M cash, $5.2M drawn on credit facility, total assets $71M, equity $21.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91198,"accession_number":"0001087294-26-000043","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cumberland shareholders elect two Class I directors, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Kenneth J. Krogulski elected with 99.52% votes in favor; Caroline R. Young with 98.66%.","Ratification of Carr, Riggs & Ingram as auditor for FY 2026 received 99.82% approval.","Advisory vote on executive compensation passed with 99.82% votes in favor.","Frequency vote: every three years for say-on-pay received 7,844,848 votes vs 1,733,309 for every year.","All proposals passed; annual meeting held April 21, 2026 in Nashville, Tennessee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91197,"accession_number":"0001104659-26-047335","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Cumberland Pharma sells commercial products to Apotex for $100M, retains pipeline","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Apotex acquires six FDA-approved brands (Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ) for $100M cash.","Cumberland retains ifetroban pipeline (DMD, SSc, IPF) and majority stake in CETI.","Deal requires shareholder approval; directors & officers holding ≈41% of shares signed voting agreements to support.","Either party may owe $4M termination fee under conditions; closing targeted by August 20, 2026.","Board and financial advisor VelocityHealth opined $100M consideration fair and reasonable to Cumberland."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101158,"accession_number":"0001087294-26-000015","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cumberland Pharma reports Q4 revenue up 31% to $13.7M; full-year adjusted earnings $1.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 net revenue $44.5M (+18% YoY); net loss improved to $2.9M from $6.5M.","Adjusted earnings for 2025 were $1.7M vs. -$1.0M in 2024; operating cash flow $4.9M.","Debt reduced by $10M; credit facility balance $5.2M at year-end; shareholders equity $24.9M.","Vibativ approved in China; launched in Saudi Arabia; Talicia co-commercialization began Oct 2025.","Caldolor received permanent J-code (J1741) for CMS reimbursement in Dec 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101157,"accession_number":"0001087294-26-000011","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cumberland Pharma gets FDA Fast Track for ifetroban in DMD heart disease","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA Fast Track Designation granted for ifetroban targeting fatal heart disease in Duchenne muscular dystrophy.","Designation follows previous Orphan Drug and Rare Pediatric Disease Designations for same indication.","Phase 2 FIGHT DMD trial showed 5.4% improvement in left ventricular ejection fraction over 12 months.","Fast Track enables expedited review, rolling submission, and more frequent FDA interactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117507,"accession_number":"0001087294-25-000023","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2025-11-24T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Cumberland amends credit line: reduces revolver to $15M, extends maturity to Oct 2027","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal available reduced to $15M (from $20M); right to request additional $10M (up from $5M).","Maturity extended to October 1, 2027; interest rate is Benchmark Term SOFR + 2.75%.","New financial covenant: Minimum Fixed Charge Coverage Ratio of 1.75x, replacing Maximum Funded Debt Ratio.","Borrowing Base Requirements made permanent; company paid $15,000 amendment fee.","Collateral remains substantially all assets; credit line with Pinnacle Bank."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117506,"accession_number":"0001087294-25-000017","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cumberland Pharma reports Q3 net loss of $1.9M; YTD revenue up 12% to $30.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue for Q3 2025 was $8.3M; YTD $30.8M (+12% vs. 2024).","Net loss Q3 $1.9M; YTD net loss $1.4M. Adjusted loss Q3 $0.8M ($0.06/sh); adjusted earnings YTD $1.9M ($0.13/sh).","Added Talicia via joint venture with RedHill: Cumberland invests $4M for 30% ownership; net revenue split equally.","Vibativ launched in Saudi Arabia; ibuprofen injection approved in Mexico; Vibativ available through Vizient.","Ifetroban Phase II DMD showed 5.4% cardiac improvement; Phase II SSc enrollment complete; IPF trial enrolling."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":30842780.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117505,"accession_number":"0001087294-25-000012","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cumberland Pharmaceuticals forms joint venture with RedHill to commercialize Talicia H. pylori therapy","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cumberland and RedHill form new jointly owned company; Cumberland provides $4M in investment capital.","RedHill contributes all Talicia assets; Cumberland handles distribution and records product sales.","Talicia generated $8M net revenue in 2024; both companies equally share net revenues.","Talicia is FDA-approved for H. pylori, patent protected through 2042, with QIDP exclusivity.","Product has broad insurance coverage: 70% commercial, 60% government; CVS stocks at 1,700 pharmacies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133919,"accession_number":"0001628280-25-037923","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cumberland Pharma reports Q2 revenue up 10% YoY; YTD revenue +23%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net revenue $10.8M (+10% YoY); YTD net revenue $22.6M (+23%).","Q2 net loss $741k; YTD net income $516k; adjusted YTD EPS $0.18.","Ifetroban Phase II DMD trial showed 5.4% improvement in cardiac function; FDA submission completed.","Vibativ 4-vial starter pak now available via Vizient, covering >65% of U.S. acute care providers.","Cash and equivalents $16M; total assets $68M; shareholders' equity $28M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":22550418.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150663,"accession_number":"0001628280-25-022753","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cumberland Q1 revenue $11.7M (+38% YoY), net profit $1.3M; DMD Phase II positive, Vibativ China OK","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $11.7M vs $8.5M prior year, 38% increase.","Net income $1.3M; adjusted earnings $2.4M ($0.16/shr); operating cash flow $3.9M.","Positive Phase II data for ifetroban in Duchenne muscular dystrophy; FDA end-of-phase-II meeting planned.","Vibativ approved in China; launch expected by end of 2025.","Balance sheet: $15.1M cash, $5.2M drawn on credit facility; equity $28.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":11713055.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150662,"accession_number":"0001628280-25-020222","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cumberland shareholders re-elect three directors, ratify auditor with >98% votes","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Directors Bernard, Galante, and Kazimi re-elected with 98.6%, 99.2%, and 99.6% votes in favor.","Auditor Carr, Riggs & Ingram ratified for 2025 with 99.7% votes in favor.","Annual meeting held April 22, 2025 in Nashville, Tennessee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169613,"accession_number":"0001628280-25-013875","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cumberland's ifetroban shows 5.4% cardiac improvement in DMD Phase 2 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["High-dose ifetroban improved LVEF by 3.3% vs. placebo and 5.4% vs. natural history controls.","Results from FIGHT DMD trial selected for late-breaking presentation at MDA Clinical & Scientific Conference.","Ifetroban has FDA Orphan Drug and Rare Pediatric Disease Designations for DMD heart disease.","End-of-Phase-2 meeting with FDA planned to discuss next steps for development and commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169612,"accession_number":"0001628280-25-009967","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cumberland Pharma Q4 revenue +11.6% to $10.4M; full-year net loss $6.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net revenue $10.4M, up 11.6% YoY; full-year revenue $38M.","Full-year net loss $6.4M; adjusted loss $1.0M (excl. $1.3M product acquisition costs).","Cash $18M, total assets $76M, liabilities $53M, shareholders' equity $23M at year-end.","Phase 2 ifetroban DMD study positive top-line; Vibativ approved in China.","Kristalose $15.3M, Sancuso $9M, Vibativ $7.2M, Caldolor $5M in 2024 revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169611,"accession_number":"0001628280-25-006430","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cumberland gets NMPA approval in China for Vibativ; exclusive deal with SciClone","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Vibativ (telavancin) approved by China's NMPA for hospital-acquired pneumonia, ventilator-associated pneumonia, and complicated skin infections.","SciClone granted exclusive rights to register, promote, and distribute Vibativ in China.","Companies plan to launch Vibativ in China later in 2025.","Vibativ is a once-daily IV antibiotic designed to treat multidrug-resistant Gram-positive bacteria."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169610,"accession_number":"0001628280-25-005744","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cumberland Pharmaceuticals increases ATM offering size to $10M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Maximum aggregate offering price under Sales Agreement with H.C. Wainwright raised to $10,000,000.","Prospectus supplement filed February 14, 2025, amending prior $0 limit or undisclosed prior cap.","Shares of common stock (CPIX) may be sold at-the-market from time to time.","No specific use of proceeds stated in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169609,"accession_number":"0001628280-25-003753","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cumberland Pharma Phase 2 ifetroban trial meets primary endpoint in DMD heart disease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["High-dose ifetroban (300mg/day) produced 3.3% LVEF improvement vs placebo decline of 1.5%, net 4.8% benefit.","Comparison with propensity-matched natural history controls showed 5.4% overall LVEF improvement in high-dose group.","Both doses were well-tolerated; no serious drug-related events reported among 41 enrolled DMD patients.","Ifetroban holds FDA Orphan Drug and Rare Pediatric Disease Designations; first Phase 2 study for DMD heart disease.","Company plans end of Phase 2 FDA meeting to discuss development path; potential first therapy for DMD cardiomyopathy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186675,"accession_number":"0001628280-24-050499","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA approves simplified dosing regimen for Cumberland's Acetadote IV NAC","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved sNDA for Acetadote on Dec 9, 2024; new regimen combines first two bags into a single slower infusion.","New dosing aims to reduce medication errors and non-allergic anaphylactoid reactions (NAARs) without compromising efficacy.","Acetadote indicated to prevent/lessen liver injury after acetaminophen overdose, the leading cause of acute liver failure in the US.","Cumberland Pharmaceuticals (CPIX) specialty pharma; CEO A.J. Kazimi highlighted commitment to improving patient care."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186674,"accession_number":"0001628280-24-046827","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cumberland Pharma receives FDA Orphan Drug and Rare Pediatric Disease designations for Ifetroban in DMD","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Orphan Drug and Rare Pediatric Disease Designations to Ifetroban for cardiomyopathy associated with Duchenne muscular dystrophy.","Cumberland is completing the FIGHT DMD Phase II trial; results expected later in 2024.","Rare Pediatric Disease Designation may qualify company for a priority review voucher upon approval.","Orphan Drug Designation provides seven-year market exclusivity, tax credits, and fee waivers if approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186673,"accession_number":"0001628280-24-046399","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cumberland Pharma Q3 net loss $1.5M; Caldolor study, DMD designations announced","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024 net revenue $9.1M; net loss $1.5M ($0.11 loss per share); adjusted loss $0.26M ($0.02 per share).","Real-world study of 150k patients shows Caldolor associated with fewer adverse drug reactions vs ketorolac.","FDA grants Orphan Drug and Rare Pediatric Disease designations for ifetroban in Duchenne Muscular Dystrophy.","Kristalose added to Medicaid plans in VA, LA, ME; Vibativ partner in Saudi Arabia begins ordering for launch.","Phase II MENDING trial for delirium meets primary safety endpoint; CET plans pivotal study discussion with FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":27432376.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186672,"accession_number":"0001628280-24-045807","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cumberland announces study showing Caldolor reduces adverse drug reactions vs ketorolac","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Study analyzed records of >17M patients; compared 31,046 Caldolor vs 124,184 ketorolac adults.","Caldolor associated with 45% reduction in renal dysfunction (p<0.001) and 78% fewer hematuria events.","In pediatric patients, Caldolor showed 51-65% lower rate of adverse drug reactions.","Caldolor also linked to decreased ER visits and shorter hospital stay for both adults and children."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186671,"accession_number":"0001628280-24-045054","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CMS denies Caldolor separate Medicare reimbursement under NOPAIN Act for CY2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS excluded Caldolor from NOPAIN Act separate payment list announced Nov 1, 2024 for CY2025.","CMS concluded Caldolor does not qualify because FDA indication lacks mention of post-operative use.","Company submitted comments in July 2023 and July 2024 arguing Caldolor meets statutory requirements.","Company says majority of Caldolor use is surgical and FDA approval based on post-surgical pain studies.","Cumberland is evaluating options; calls CMS determination inconsistent with NOPAIN Act intent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203236,"accession_number":"0001628280-24-035262","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cumberland Pharma Q2 revenue $9.9M, up 16% sequentially; adjusted earnings positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net revenue $9.9M, 16% increase from Q1 2024; year-to-date $18.3M.","Adjusted earnings $0.2M ($0.01/share), a $0.8M improvement vs prior Q1 period.","Net loss $1.1M ($0.08/share) in Q2; year-to-date net loss $3.0M ($0.21/share).","Product revenue: Kristalose $4.1M, Vibativ $2.5M, Sancuso $2.2M, Caldolor $0.8M in Q2.","Cash $17.3M; $16.1M drawn on credit line; total assets $78.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":18346550.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219566,"accession_number":"0001628280-24-021185","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cumberland Pharmaceuticals Q1 net loss $1.9M; revenue $8.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $8.5M; Kristalose $3.2M, Sancuso $1.8M, Vibativ $1.6M, Caldolor $1.5M.","Net loss $1.9M ($0.14/share); adjusted loss $0.6M ($0.05/share).","Cash $19M, total assets $82M, liabilities $54M, equity $27M.","Caldolor highlighted in NOPAIN Act; CMS decision pending for 2025 Medicare reimbursement.","Ifetroban enrollment underway for Idiopathic Pulmonary Fibrosis trial (128 patients)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":8497701.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219565,"accession_number":"0001628280-24-019053","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cumberland Pharmaceuticals shareholders re-elect directors, ratify auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Martin S. Brown, Jr. re-elected as Class II director with 96.0% of votes in favor (8,544,756 for, 352,239 withheld).","James R. Jones re-elected as Class II director with 94.5% of votes in favor (8,411,468 for, 485,527 withheld).","Ratification of Carr, Riggs & Ingram LLC as auditor for FY2024 passed with 99.9% of votes in favor (11,189,440 for, 15,502 against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239377,"accession_number":"0001628280-24-012261","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2024-03-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cumberland Pharmaceuticals launches $5.8M at-the-market equity offering with H.C. Wainwright","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM program filed March 20, 2024 for up to $5.8M of common stock through H.C. Wainwright as sales agent.","Sales agent will receive 3.0% commission on gross proceeds from shares sold under the agreement.","Proceeds intended for working capital, R&D expenses, capital expenditures, and general corporate purposes.","Sales may occur at prevailing market prices; company may set minimum price or suspend offering at any time.","Offering terminates upon sale of all shares or termination of agreement by either party on five days' notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239376,"accession_number":"0001628280-24-009006","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cumberland Pharma reports 2023 net loss of $6.3M; revenue $40M; Caldolor labeling expanded to infants","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $6.3M for 2023, includes $3.3M non-cash charge on product discontinuation; adjusted earnings $2.4M ($0.17/share).","Revenue $40M from four brands: Kristalose $16M, Vibativ $8.8M, Sancuso $8.1M, Caldolor $4.3M.","FDA approved expanded Caldolor labeling for infants 3-6 months; only non-opioid injectable for pain/fever in that age group.","NOPAIN Act expected to provide favorable CMS reimbursement for Caldolor starting 2025; company submitted request.","Ifetroban Phase II trials ongoing for DMD, scleroderma, IPF; FDA grants >$1M; oral capsule study initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256911,"accession_number":"0001628280-23-037446","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cumberland Q3 2023: net loss $1.0M, revenue $10.1M, YTD adj. EPS $0.29","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $1.0M; adjusted earnings $260K ($0.02/share); YTD net income $15K, adj. EPS $0.29.","Product revenue $10.1M (Kristalose $3.9M, Vibativ $2.8M, Sancuso $1.9M, Caldolor $1.2M).","New $25M revolving credit facility with Pinnacle Bank; $12.9M drawn at quarter-end.","Sancuso acquisition transition completed; FDA approved new mfg plant; supplies underway Q4 2023.","NOPAIN Act may provide separate Medicare reimbursement for Caldolor from 2025; ifetroban Phase II trials ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":30199441.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256910,"accession_number":"0001628280-23-034316","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2023-10-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cumberland Pharma announces pediatric Vibativ safety study publication","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First clinical study of Vibativ in children 2–17; single 10 mg/kg dose safe with no serious adverse events.","Published in Antimicrobial Agents and Chemotherapy; 22 patients enrolled.","Study found lower drug exposure in children vs adults, informing future dosing.","Vibativ is FDA-approved for adult HABP/VABP and cSSSIs caused by gram-positive bacteria."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274245,"accession_number":"0001628280-23-031458","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2023-09-06T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Cumberland enters new $25M credit facility with Pinnacle Bank; prior $5.1M transferred","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New revolving credit line up to $20M, expandable to $25M, 3-year term to Oct 1, 2026.","Interest at Term SOFR + 2.75%; single financial covenant: Funded Debt Ratio tested quarterly.","Prior $5.1M outstanding balance transferred from old 2017 agreement; no early termination penalties.","Proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274244,"accession_number":"0001628280-23-028289","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cumberland Pharma Q2 revenue $10.9M (+6% YoY); net income $0.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net revenue $10.9M (+6% vs prior year, +18% sequential); YTD revenue $20.1M.","Q2 net income $0.9M ($0.06/diluted share); YTD net income $1.1M ($0.07/share).","Adjusted Q2 earnings $2.3M ($0.16/share); YTD adjusted $4.0M ($0.27/share).","FDA approved Caldolor for infants (3-6 months) in May; study results published June.","Received $2.8M in FDA barrier-to-innovation fee waivers in June 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":20113515.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291451,"accession_number":"0001628280-23-024065","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2023-06-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cumberland reports ifetroban well-tolerated with positive trend in DMD trial; no stat-sig","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Interim analysis from 25 patients after 6 months; both ifetroban doses well-tolerated.","Positive trend in leg muscle strength but no statistically significant differences at this early point.","Phase II trial evaluating ifetroban for DMD cardiomyopathy; FDA awarded $1M orphan grant.","Company plans to complete studies, analyze data, then decide development path for ifetroban registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291450,"accession_number":"0001628280-23-022935","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2023-06-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cumberland settles breach-of-contract suit with Melinta/Targanta, receives undisclosed consideration","summary_kind":"llm","event_type":"litigation","confidence":"low","bullets":["Settlement finalized June 16, 2023; case closed in NY Supreme Court.","Company had sought $1M in milestone payments for NDA/sNDA filings.","Defendants obtained license to Company patents for product development.","Original action filed Feb 2022; refiled Nov 2022 after jurisdiction change."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291449,"accession_number":"0001628280-23-021318","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2023-06-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cumberland Pharmaceuticals receives FDA waiver, $1.2M refund for RediTrex fees","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted barrier-to-innovation waiver based on ifetroban clinical programs addressing unmet medical needs.","Company will receive refund of approximately $1.2 million in prescription drug program fees for RediTrex.","Refund expected within 45 days from FDA's Office of Financial Management.","Waiver follows Cumberland's April 3, 2023 request for reconsideration through counsel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291448,"accession_number":"0001628280-23-020697","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2023-06-02T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"Cumberland Pharmaceuticals appoints Carr, Riggs & Ingram as new independent auditor for FY 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Appointed CRI as independent registered public accounting firm for FY ending Dec 31, 2023, effective for interim period ending June 30, 2023.","No prior consultations with CRI on accounting principles or audit opinion type.","No disagreements or reportable events between the company and predecessor auditor as defined in Regulation S-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291447,"accession_number":"0001628280-23-019604","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2023-05-24T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Cumberland Pharmaceuticals dismisses FORVIS as auditor, appoints CRI for FY2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective May 18, 2023, dismissed FORVIS as independent auditor; new auditor is Carr, Riggs & Ingram (CRI) subject to engagement letter.","No disagreements on accounting principles, financial statement disclosure, or audit scope during 2021-2022 and interim 2023.","FORVIS audit reports for 2021 and 2022 were unqualified, no adverse opinion or modification.","Company provided FORVIS with disclosures; FORVIS furnished letter to SEC agreeing with statements (Exhibit 16.1).","No consultations with CRI regarding accounting principles or disagreements prior to appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291446,"accession_number":"0001628280-23-018467","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2023-05-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA approves Caldolor for infants aged 3-6 months; only injectable non-opioid for pain/fever in that age group","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approval expands Caldolor label to include infants 3 months to 6 months for pain and fever.","Caldolor is now the only injectable non-opioid approved for pain treatment in infants.","Approval based on a multi-center study in 21 hospitalized infants; safety and efficacy established from age 3 months.","The company expects Caldolor to be eligible for special Medicare reimbursement under the NOPAIN Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291445,"accession_number":"0001628280-23-016892","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cumberland Pharma Q1 net revenue $9.2M, adj. EPS $0.11; expects Caldolor Medicare boost under NOPAIN Act","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2023 net revenues of $9.2M; net income of $0.2M ($0.01 EPS); adjusted earnings of $1.7M ($0.11 EPS).","Product revenue: Kristalose $4.3M, Sancuso $1.9M, Vibativ $1.8M, Caldolor $0.9M.","Caldolor expected to qualify for separate Medicare reimbursement under the NOPAIN Act, enacted April 2023.","FDA granted barrier-to-innovation waiver, refunding nearly $2M in RediTrex prescription drug program fees.","Balance sheet: $89M assets, $16M cash, $53M liabilities (including $16M drawn on revolver), $36M equity."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":9224638.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291444,"accession_number":"0001628280-23-014265","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2023-04-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cumberland shareholders elect directors, ratify auditor, approve say-on-pay and incentive plan amendment","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class I directors Krogulski (99.1%) and Young (90.7%) elected; Class II director Brown (98.6%) elected.","Ratification of FORVIS as auditor for 2023 received 99.1% votes in favor.","Advisory say-on-pay resolution approved with 89.9% votes in favor.","Amendment to 2007 Long-Term Incentive Plan approved with 75.0% votes in favor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291443,"accession_number":"0001628280-23-011672","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2023-04-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cumberland Pharma's Caldolor expected to qualify for separate Medicare reimbursement under NOPAIN Act from 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NOPAIN Act requires Medicare to provide separate reimbursement for non-opioid pain management products in outpatient hospital and ambulatory surgical center settings.","Caldolor (ibuprofen injection) is a non-opioid analgesic indicated for pain management, shown to reduce opioid use.","Reimbursement applies to products furnished between Jan 1, 2025 and Jan 1, 2028; CMS to issue regs in 2024.","Caldolor is FDA approved for mild to severe pain in adults and pediatric patients age 6 months+.","Company expects this will positively impact Caldolor's Medicare reimbursement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291442,"accession_number":"0001628280-23-010469","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2023-04-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA grants barrier-to-innovation waiver; Cumberland to receive ~$1.9M refund for RediTrex fees","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA reversed prior denial and granted barrier-to-innovation waiver on March 30, 2023, after reconsideration request.","Refund of approximately $1.9 million in prescription drug program fees for RediTrex expected within 45 days.","Waiver tied to Cumberland's ifetroban clinical programs addressing unmet medical needs.","Original $1.9M fee paid Oct 4, 2021; initial denial Nov 1, 2021; reconsideration filed Nov 28, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312256,"accession_number":"0001628280-23-007952","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2023-03-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Cumberland Pharmaceuticals enters new employment agreements with five officers, including CEO at $675k salary","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO A.J. Kazimi base salary set at $675,000; effective January 1, 2023.","EVP James Herman salary $310,000; VP Todd Anthony $272,500; VP Chris Bitterman $258,500; CFO John Hamm $228,000.","All agreements are at-will with no severance for cause, death, or permanent disability.","No change-in-control or termination provisions; include non-compete, non-solicitation, confidentiality covenants.","Agreements dated March 9, 2023, effective retroactively to January 1, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312255,"accession_number":"0001628280-23-006782","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2023-03-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cumberland Pharma reports 17% revenue growth to $42M in FY2022; adj. EPS $0.14","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2022 revenue $42.0M (+17% YoY); net loss $5.6M ($0.38/sh); adj. earnings $2.1M ($0.14/sh) vs adj. loss $1.2M in 2021.","Q4 revenue $9.1M; net loss $2.4M; adj. loss $0.7M ($0.05/sh) vs adj. loss $1.9M in Q4 2021.","Cash from operations $8.5M vs $6.3M prior year; balance sheet: $20M cash, $57M liabilities, $36M equity.","Product revenue: Kristalose $15.2M, Sancuso $13.2M, Vibativ $7.5M, Caldolor $4.8M.","Acquired Sancuso from Kyowa Kirin in 2022; new Nashville HQ; international partnerships for Vibativ and Caldolor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312254,"accession_number":"0001628280-23-001129","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2023-01-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cumberland Pharmaceuticals Board member Joey A. Jacobs dies; board to reassign duties","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joey A. Jacobs, Board member since 2011, passed away on January 14, 2023.","He served as Lead Independent Director and Chairman of Governance/Nominating Committee.","Jacobs had over 45 years of healthcare industry experience.","Former CEO of Acadia Healthcare and co-founder of Psychiatric Solutions (PSI).","Board will meet to reassign his responsibilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330832,"accession_number":"0001628280-22-031743","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2022-12-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA approves new manufacturing site for Cumberland's Sancuso; $1M milestone due","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved Kindeva as new manufacturing and packaging site for Sancuso on Dec. 6, 2022.","Cumberland acquired U.S. rights to Sancuso in Jan. 2022; Kyowa Kirin led the FDA submission.","Cumberland will pay Kyowa Kirin a $1 million milestone payment following the approval.","Sancuso is the first FDA-approved transdermal patch for chemotherapy-induced nausea/vomiting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330831,"accession_number":"0001628280-22-028987","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cumberland Q3 revenue up 41% to $11.4M; net loss narrows to $0.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $11.4M vs $8.1M a year ago, driven by Sancuso ($4.0M) and Kristalose ($3.9M).","Net loss improved to $0.4M from $1.1M; adjusted earnings $1.4M ($0.10/share).","Year-to-date cash from operations $5.6M, up 28% from $4.4M.","Completed Sancuso transition under co-promotion with Verity; RediTrex amendment allows Nordic to assume U.S. commercialization after March 2023.","Phase II ifetroban trials ongoing; AERD study closed to enrollment awaiting top-line results."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":11413072.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-11-08T23:59:59+00:00|330831"}